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The ultimate goal of the global programme against lymphatic filariasis is eradication 
through irrevocable cessation of transmission using 4 to 6 years of annual single dose 
mass drug administration. The costs of eradication, and logistical and managerial 
impediments to executing national and regional control programmes, and scientific 
uncertainty about transmission endpoints, are challenges to the success of this effort, 
especially in areas of high endemicity where financial resources are limited.  We used a 
combined analysis of empirical community data describing the association between 
infection and chronic disease prevalence, mathematical modelling, and economic 
analyses to identify and evaluate the feasibility of setting an infection target level at 
which the chronic pathology attributable to lymphatic filariasis - lymphoedema of the 
extremities (elephantiasis) and hydroceles - becomes negligible in the face of continuing 
transmission as a first stage option in achieving the elimination of this parasitic disease.  
The results show that microfilaria prevalences below a threshold of 3.55% at a blood 
sampling volume of 1ml could constitute readily achievable and sustainable targets to 
control disease due to lymphatic filariasis. They also show that as a result of the high 
marginal cost of curing the last few individuals to achieve elimination, maximal benefits 
can occur at the disease control threshold. Indeed, a key finding from our coupled 
economic and epidemiological analysis is that when initial uncertainty regarding 
eradication occurs and prospects for improving information to resolve such uncertainty 
over time exist, it is economically beneficial to adopt a flexible, sequential, eradication 
strategy based on controlling chronic disease initially. These results suggest that it may 
be optimal to set phased targets for the elimination of lymphatic filariasis, starting with 
disease control followed by intensified efforts to eradicate transmission as better 
knowledge regarding transmission dynamics and issues of implementation feasibility 
becomes evident. They also illustrate the importance of taking explicit accounts of 
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uncertainties, multi-staged endpoints, and the value of embedding flexibility in the 
decision making process when determining optimal parasite eradication strategies. 
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Given that the health and economic dividends of the current global campaign to eradicate 
lymphatic filariasis (LF) by mass drug administration (MDA) could be large 1,2, a strategy 
that has as its ultimate goal the sustained interruption of transmission of this mosquito-borne 
infectious disease represents the optimal policy from a social perspective 3. This optimality, 
as for any parasite control programme, can be tempered, however, by the technical challenge 
of maintaining adequate population coverage with MDA necessary to achieve cessation of 
transmission within the currently mooted period of 4 to 6 years and the financial burden of 
continuing intervention programmes that target the last few communities and individuals 
necessary to meet criteria considered to be indicative of eradication 3. Moreover, achieving 
parasite eradication implies the need for sustaining control programmes in order to continue 
surveillance for residual infections beyond 4 to 6 years 4.  Current scientific understanding of 
LF eradication is also hampered by imperfect knowledge regarding parasite transmission 
dynamics and endpoint targets 5. 
 Recent work has clarified the economic behaviour of investments in parasite 
eradication 3,6,7. A key notion regarding the desirability of undertaking parasite eradication 
from this perspective is that incurring immediate costs is expected to yield high future long-
term benefits. An important caveat of these appraisals is that most of this work have assumed 
the technical feasibility of eradication with little focus given so far to the role of payoff 
uncertainty on the choice of optimal strategies. These gaps in analysis are particularly 
significant when considering recent work carried out in the field of strategic management, 
which shows that when longer-term investment outcomes are uncertain, it may be optimal to 
identify and implement effective strategies over the short term, which can be adapted flexibly 
to achieve investment goals as information regarding the attainability of desired outcomes 
improves in time 8-10.  
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These considerations suggest that in certain geographical regions, especially in sub-
Saharan Africa and other areas where LF endemicity are high and budgetary and capacity 
constraints apply, it may be desirable to adopt flexible strategies that first reduce infection to 
levels that prevent the occurrence of LF disease manifestations even though a steady state, 
low level of transmission persists. Although it is not yet known whether such a strategy 
would be successful, empirical observations from some MDA trials have shown that the 
prevalence of the major chronic disease manifestations of LF, lymphoedema of the 
extremities and hydrocele, can be decreased without reducing transmission levels to zero 11,12.  
Here, we use epidemiological analyses of observed data describing the relationship between 
the overall prevalence of chronic bancroftian filarial disease and microfilarial (mf) infection 
in conjunction with mathematical model predictions of filariasis reinfection coupled with 
economic analysis of MDA interventions, to estimate and clarify the value of using a 
threshold infection level below which LF-related pathology becomes negligible as a first 
stage option in the successful eradication of LF.  
 
Results 
Figure 1 depicts the data collated from all relevant published studies available from Sub-
Saharan Africa and India on the association between the community prevalence of LF 
infection and the corresponding prevalence of chronic disease (n=76). Despite the presence of 
some between-region geographic variation, the scatterplot depicted in the figure shows that 
there is a global occurrence of an overall positive but non-linear association between chronic 
disease attributed to LF and mf infection, with disease apparently constant up to a threshold 
mean mf prevalence level and then increasing positively. Such a disease-infection pattern, 
shown here for the first time for LF, suggests the operation of an infection dose response 
function whereby in communities with low mf prevalence the observed disease may be due to 
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causes other than filariasis while disease attributable to filarial infection develops only above 
a specific mf threshold 13. Table 1 shows the results of the statistical fits of models 1 and 2 to 
the data, and supports the visual impression from Figure 1 of the existence of an “average” 
mf threshold in the development of LF chronic disease in the present data. The curve in the 
figure portrays the predictions of the logistic regression-based dose response model 
incorporating a threshold (model 2), and indicates that the pattern illustrated by the data for 
the occurrence of a threshold dependent dose-response in the association between LF 
infection and disease is adequately described by this model (see Supplementary Method 
online for details of goodness of fit of the model). This result indicates that a threshold mf 
prevalence value that could be used as a target for suppressing formation of filarial disease 
may lie in the region of 3.55% (95% confidence limits: 2.35 – 4.75) at the 1ml blood 
sampling volume scale (Table 1), with the caveat that there could undoubtedly be regional 
differences in the value of this threshold among endemic communities based on the peculiar 
features of local mosquito-vector parasite interactions.  The results also indicate that on 
average up to 1.07% of the observed lymphoedema and hydrocele cases may be non-filarial 
in aetiology 14. 
Figure 2a shows how predictions of a mathematical model of filariasis transmission 15-
17 allow an examination of the usefulness of implementing a 5-year MDA strategy with 
DEC/ALB or IVM/ALB that has as its target either parasite elimination and eradication (set 
to be around 0.5% mf prevalence here 5) or disease control (3.55% mf prevalence).  The 
simulations in the figure are all based on a moderately high overall community pre-control mf 
prevalence of 10% (at the scale of 1ml blood sampling volume), and for each treatment 
regimen are illustrated for coverage values of 65%, 80% and 95% (portrayed by curves going 
from bottom to top respectively for each drug regimen). The results indicate that while 
neither MDA regimen achieved the parasite elimination target for all the three treatment 
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coverages considered, both achieved the disease control target of 3.55% mf prevalence before 
5 years.  This was true even in the case of the less effective IVM/ALB regimen given at the 
lowest MDA coverage of 65%.  An additional feature of the results is that following the end 
of the treatment programme, the rates of rebound of infection (given that transmission has not 
been interrupted) are also predicted to be slow.  For the IVM/ALB regimen with only 65% 
population coverage, infection levels reduced to ~ 2.35% are predicted to remain under the 
disease control threshold for at least 7 years after cessation of the 5-year intervention 
programme.  At higher coverages, and for the more effective DEC/ALB regimen, infection 
levels remained below the threshold level for more than 10 years (Fig. 2a).  
This effect of the achieved post-control mf prevalence following MDA on the rate of 
return of infection prevalence to pre-control equilibrium values is more clearly shown in 
Figure 2b, and indicates how this relationship can be used to guide the setting of the mf 
prevalence target for long-term disease control. Thus, the numerical projections in Figure 2b 
indicate that reducing mf prevalence to below 2.35% (i.e. below the lower 95% CL value of 
the disease control threshold (Table 1)) may maintain infection levels below the disease 
incidence threshold of 3.55% mf prevalence for up to as long as ~10 to 12 years before repeat 
MDAs will be required to depress infection again to sustain the control of disease. This 
dynamical epidemiological result clearly makes disease control both a feasible and 
sustainable option in endemic communities.     
Table 2 summarizes and compares the predicted average and marginal costs of the 
annual IVM/ALB MDA programme (80% coverage) in curing individuals of mf to achieve 
LF elimination in Tanzania. The results show that for both types of cost estimations (the total 
economic and the financial costs of programme delivery only by the Ministry of Health), the 
average cost per individual cured of mf to achieve disease control will be moderately low 
whereas the average and marginal cost of curing additional individuals at each subsequent 
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MDA round until transmission elimination is achieved will increase steeply. This is because, 
as the number of MDA rounds increase (an additional 5 years of MDA is predicted to be 
required to achieve transmission elimination as compared to 5 years of MDA in total to 
achieve long-term disease control, ie., by achieving mf prevalence reduction to 2.35% 
following annual MDA (see above)), a progressively decreasing proportion of individuals are 
cured at the same fixed outlay for implementing the annual mass treatment programme. For 
example, only an extra 0.32 million individuals are cured of mf over the additional 5 MDAs 
to meet the target of transmission elimination as compared to the 2.5 million cured over 5 
years to achieve long-term disease control (Table 2). Because the number of MDA rounds 
required to achieve disease control is smaller than that required to achieve transmission 
elimination (indeed, in general this will take half the time required for parasite elimination 
(results not shown)), the marginal cost of achieving disease control will also be considerably 
smaller compared to that for achieving parasite elimination. The analysis presented here used 
a very conservative cost of $0.70 in the case of the total economic cost approach and $0.53 in 
the case of the Government cost method to treat one individual 18-21; increasing this cost will 
only further amplify the present findings. 
Indeed, in cost-effectiveness terms, the declining number of additional individuals 
cured as annual MDA proceeds compared to the increasing marginal cost of curing these 
individuals from the additional cycles of MDA suggests that theoretically maximal benefits 
may occur at less than 100% parasite control or parasite elimination. This is highlighted in 
Figure 3, which graphically compares the expected effectiveness and costs of the annual 
MDA programme to eliminate LF in Tanzania.  Figure 3 shows that the maximal cost-
effectiveness of the programme could occur at 85% parasite control following 3 annual 
MDAs. This is closer to the predicted 5 cycles of annual MDA required to achieve long-term 
disease control for this country (Table 2) in contrast to the 10 annual cycles needed to achieve 
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parasite elimination or 100% parasite control, and further supports the soundness of a disease 
control option as a first phase intermediate objective in efforts to eradicate LF.  
This incremental role of controlling disease first in LF eradication is reinforced by the 
estimates of the expected present value costs (EPVCs) of LF eradication strategies for the 
Republic of Tanzania with and without a flexible sequential-decision option based on 
exercising disease control option, shown in Table 3. The number of years needed to achieve 
LF disease control or/and eradication were based on EPIFIL model predictions as described 
in Methods, while similar treatment costs and discount rates as utilized in the marginal cost-
effectiveness analysis were used in the analysis for comparative purposes. The results depict 
that the EPVCs of strategies that contain the flexibility of switching between disease control 
and eradication are always lower than that of an eradication strategy in which no flexibility to 
either switch to disease control if eradication is not feasible or to embark upon eradication 
after disease control when eradication becomes favourable exists. Since the EPVCs of the 
flexible strategies are always lower than that of the inflexible eradication strategy, it is clear 
that such strategies should always be preferable highlighting their optimality when 
uncertainty regarding eradication occurs. Indeed, the results show that switching to long-term 
disease control from year 5 (MDAs given every 10 years following an initial 5 annual MDAs 
to achieve disease control: Strategy 2) can be the cheapest intervention option for LF if 
eradication can never be achieved (Table 3),  while the lower EPVCs of Strategies 3a & b 
compared to Strategy 1 highlight the costs which can be saved by waiting for better 
information regarding the feasibility of eradication before switching to eradication from 
disease control. The value of including such flexibilities in the LF eradication programme for 
the republic of Tanzania is given by option value figures depicted in Table 3, and indicates 
that including flexible decision-making based initially on disease control can yield savings of 
between US$ 3.3 to 5.0 million depending on the feasibility of eradication (from never 
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(Strategy 2) to waiting to switch to eradication at different times when knowledge and 
technology improves (Strategies 3a & 3b)).  
Figure 4 shows the relationship between the probability of eradication (the lower this 
probability the higher the uncertainty regarding the feasibility of eradication) and the EPVC 
values of strategies 3a and 3b. The results clearly show that as uncertainly regarding 
eradication increases the EPVCs of these strategies will decline dramatically, indicating the 
important result that inclusion of flexibility using chronic disease control should be even 
more preferable when uncertainty regarding eradicability is high. For example, when 
uncertainty regarding eradication is even moderately high, say at the probability of 
eradication of only p= 0.70, the costs saved (or option value of) employing Strategy 3a over 
the inflexible Strategy 1 can be as high as US$10.0 million and for Strategy 3b even higher at 
US$12.0 million. Note that because of the effects of discounting, Strategy 3b will always be 
better value than Strategy 3a as the extra costs related to switching to eradication occurs 5 
years later compared to the case with the latter strategy (Table 3).    
 
Discussion 
This study set out to use a combined epidemiological and economic approach in order to 
evaluate the possibility of estimating and setting an infection threshold that achieves control 
of LF-related disease as a rational and feasible first stage target for LF eradication 
programmes. Our analyses show that not only may such a threshold exist epidemiologically 
but also that this endpoint is likely to be sustainable owing to the slow rebound of infection 
following MDA (principally as a result of the long life span of the adult parasite 16).  The 
results also reveal that a third epidemiological factor which may make an intervention 
strategy aimed at controlling LF morbidity as an intermediate step on the path to parasite 
eradication attractive to policy makers and health care planners in developing countries – 
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namely that disease control thresholds can generally be achieved in half the time required for 
accomplishing transmission elimination. This is shown to be the case even if the long-term 
disease control mf prevalence target is set to be lower (eg, 2.35%) than the infection 
threshold (3.55%) at which disease develops in communities. From the perspective of 
national health agencies responsible for implementing and sustaining MDA programmes, this 
finding highlights the feasibility of achieving disease control readily compared to 
transmission elimination, especially when model predictions and available data 12,22-25 suggest 
that even when high population coverage is achieved the duration of annual MDA necessary 
to stop transmission can be expected to extend beyond 7 years in the many endemic areas 
where the baseline mf prevalence is equal to or greater than 10% 5,17.  
Note that our estimate of the disease control threshold in this study was technically 
made possible only via synthetic epidemiological analysis based on using all the available 
published data from only two of the major LF endemic regions.  Given the geographic 
variation in the data used to construct Figure 1 and lack of adequate information within and 
across many other LF endemic areas, this estimated disease threshold could in reality vary 
importantly between regions. However, as noted above, the paucity of regional data 
describing the mf and disease prevalence relationship particularly at the lower range of the 
two variables currently precludes the estimation of pertinent region-specific figures and 
determination of whether the mf threshold estimated here is valid for all endemic areas that 
have or will soon participate in national MDA programmes. This conclusion, as highlighted 
also for the estimation of transmission endpoints in LF 5, signifies the need for collecting 
more reliable standardized data spanning the natural range of prevalences observed in the 
field at the regional level, especially over the lower mf and disease prevalence ranges. In the 
meanwhile, given that data from Sub-Saharan Africa were used in the estimation of the 
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disease threshold value here, we suggest that the present results for the Republic of Tanzania 
are unlikely to be severely influenced by this issue.  
The economic analyses carried out in this study have yielded two major hitherto not 
fully recognized insights regarding the choice of optimal eradication strategies for LF. First, 
marginal cost-effectiveness analysis has demonstrated that when epidemiological results are 
combined with economic rationalities, disease control as a first stage target is further likely to 
be attractive to policy makers as a result of the far higher marginal cost that arises from 
having to cure additional individuals in order to stop parasite transmission completely 
compared to controlling disease. Coupled with relatively low cost social efforts that 
emphasize local hygiene to prevent and treat forms of chronic morbidity such as 
lymphoedema of the extremity 26, this important outcome suggests that the decision to 
undertake parasite eradication must also take explicit account of the opportunity cost of 
eradication, especially when budgetary and capacity constraints exist within the health 
systems expected to implement and sustain mass intervention programmes. Indeed, our 
analysis shows that the relationship between the marginal social benefits and costs of annual 
LF MDA is such that the optimal level of parasite control may be closer to that achieved by 
disease control compared to parasite elimination. This result is obviously tempered by the 
technical feasibility of achieving parasite elimination 3, but it does indicate the possibility that 
given the slow expected rebound of infection when parasite transmission is reduced but not 
eliminated, human and financial resources that would otherwise be expended for continuation 
of MDA and infection surveillance during the period of low reinfection could be far better 
spent more beneficially on economic and social development of target populations (better 
sanitation, improved health and educational facilities, increased income-generating options). 
In purely economic terms, these findings pertaining to both the feasibility and opportunity 
cost of achieving parasite elimination underscore the well-known principle that opting for 
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first-best efforts, such as eradication or elimination, is unlikely to be attainable in a second-
best world 27-29. Instead, they suggest that Pareto optimality under these circumstances may 
well be better achieved by opting for second-best strategies, such as disease control, ie., 
optimal policy must crucially account for the feasibility of  implementing proposed strategies 
28-30.  
Although the results of the marginal cost-effectiveness analysis carried out here has 
shed light on issues underlying the economic optimality of undertaking disease control versus 
eradication, particularly that social welfare may be maximized at levels of parasite control 
below eradication levels, it is plainly restricted in its scope as it does not address the 
continuous nature of investment that would be required to maintain disease control (which 
clearly makes eradication optimal if technically feasible 31,32) nor does it address the issue of 
uncertainty in the possibility of achieving eradication. The latter is clearly an overriding issue 
for the development of optimal LF intervention strategies given the current imperfect 
scientific knowledge regarding transmission endpoint values, the duration and intensity of 
treatments required to achieve parasite elimination under different endemic conditions, and 
the potential for the emergence of drug resistance in treated worm populations 5,17,33,34, and 
problems associated with organizational capacities and finances in many endemic countries 
that are likely to affect the adequate implementation of long-term interventions. 
Here, we have attempted to address these issues via expected cost comparisons of an 
intervention aiming solely at eradication with those combining disease control with wait 
options to switch to eradication depending on when knowledge and/or technology for 
achieving eradication becomes more certain. Our primary finding is that, as with all 
investment projects, when longer-term uncertainty about programme payoffs exists, there is 
value in developing and implementing flexible, dynamic approaches that focus on identifying 
and implementing optimal shorter-term strategies (such as disease control considered here) 
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which can be adjusted (switched to eradication or even long-term disease control) according 
to future scientific progress 8-10. Our analysis illustrates that this is basically because any 
long-term decision taken now under uncertainty has an opportunity cost in that it eliminates 
the option of waiting for further information and hence the possibility of making better loss 
minimizing decisions later. We have shown that this option value for flexible sequential-
decision making under eradication uncertainty can be large depending on the nature and 
timing of flexibility and degree of uncertainty (Table 3); indeed we calculate that for 
moderate uncertainty (probability of eradication = 0.70), implementing flexible LF 
eradication strategies based on chronic disease control initially can yield cost savings (or 
option values) of up to US$12.0 million over the cost of implementing the alternate inflexible 
strategy focused solely on eradication currently being recommended for the Republic of 
Tanzania (Fig. 4).  
Analyses carried out in this study and the considerations above suggest that although 
the aim of parasite eradication by the current global initiative against LF is sound, laudable 
and likely achievable in areas of low to moderate endemicity, a strategy focused primarily or 
solely on eradication in every location, especially those where the baseline mf prevalence is 
high, could be sub-optimal. Instead, we have shown that under those circumstances and 
especially when there is initial uncertainty and there exists a possibility that knowledge 
and/or technology for effectively achieving eradication will improve with time, it is more 
desirable and cost-efficient to achieve disease control at the first instance, which can then be 
followed by a decision to intensify eradication attempts once baseline mf prevalences are 
reduced below the disease control threshold of 3.55%. In this respect, it is important to 
acknowledge how the prospects of harnessing existing and new knowledge regarding chronic 
LF morbidity control and transmission interruption, particularly the demonstrated value of 
local hygiene in treating lymphoedema 26,35,36, confirmation that MDA prevents and possibly 
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reverses pre-existing LF-related lymphedoema and/or hydrocele 12, rapid achievement of 
transmission cessation by adding vector control such as insecticide treated bed nets to MDA 
37,38, into the global strategy are likely to improve the feasibility of effective and sustainable 
parasite eradication. It is instructive in this regard to also note that morbidity due to blindness 
was achieved much more readily than transmission interruption in the case of the intervention 
program against the closely related filarial disease, onchocerciasis, in both Africa and Latin 
America 39,40. We conclude that current debates about disease control and eradication must 
include and take careful account of these factors so that richer and more comprehensive 
evaluative frameworks than simple epidemiological and investment appraisals can inform the 
design of optimal strategies to successfully achieve the control or elimination of human 
infectious diseases, particularly those occuring in the developing world. 
 
Methods 
Data Sources.  Field study data (Supplementary Table 1 online) on the association between 
the prevalence of Wuchereria bancrofti mf infection and combined lymphoedema and 
hydrocele disease rates in filarial endemic communities were extracted from the published 
literature for each of the major endemic regions of sub-Saharan Africa, Asia other than India, 
India, Latin America and the Pacific. Although this yielded data from 94 separate 
communities, perusal of the data showed that adequate data covering the full range of 
infection prevalence, especially at lower mf prevalence values, existed only for Sub-Saharan 
Africa and India. Our analysis in this study was therefore by necessity limited to these data 
compiled from a total of 76 separate communities from these two regions. Prior to analysis, 
all mf prevalence values were standardized to reflect sampling of 1ml blood volumes using a 
transformation factor of 1.95 and 1.15 respectively for values originally estimated using 20ul 
or 100ul blood volumes. These factors were derived using comparative prevalence data from 
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the parallel application of these different diagnostic methods on the same individuals 41-45, 
and the function, fp = 
*
*
20 100
ML
or
P
P
, where  P*ML  is the mean mf prevalence obtained using the 1 
ml blood filtration method and  P*20  and P* 100  denote the mf prevalences obtained using 
20ul and 100ul blood volumes 5. 
 
Statistical Analysis. The association of mf infection with chronic LF disease is described and 
the existence of a threshold in the relationship was examined via fitting of the following 
hierarchical logistic dose-response regression models with and without the specification of a 
threshold parameter to the assembled data 46-48. Model 1 represents the nonthreshold model 
and is the familiar basic logistic regression model with an intercept relating the prevalence of 
chronic LF disease to observed community mf prevalence values given by the equation: 
log
1
p x
p
α β⎛ ⎞ = +⎜ ⎟
−⎝ ⎠      (1) 
 
The threshold mf prevalence level (τ) at which parasitic infection begins to contribute 
significantly to the development of filarial chronic disease is then estimated by fitting the 
corresponding logistic dose-response model which incorporates the threshold parameter as 
depicted by the equation: 
1
log for
( )1
a Xp
a x Xp
τ
β τ τ
≤⎧ ⎫⎛ ⎞
= ⎨ ⎬⎜ ⎟ + − >−⎝ ⎠ ⎩ ⎭    (2) 
 
where p in both models is the probability of the occurrence of combined lymphoedema and 
hydrocele in the community, τ is the threshold value of the risk factor, X (i.e. mf prevalence), 
a defines the baseline morbidity prevalence due to non-filarial causes of disease, and β and β1 
describe the degree of association between infection and disease with and without the 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
56
4.
1 
: P
os
te
d 
2 
Fe
b 
20
08
 17
threshold. Model 2 assumes that the risk of chronic disease is constant below the threshold τ 
and increases according to the logistic equation above τ. Given prevalence data, we fitted the 
models assuming binomial errors and obtained parameter estimates for the data by essentially 
maximizing the log-likelihood function 13: 
• (1 ) (1 )i уi  log i +   -  уi log   - iΣ ÿ     ÿ      (3) 
 
where yi is the observed disease prevalence in each community and  i is the predicted 
prevalence of disease obtained from equations 1 and 2 respectively, given prevalence of 
infection, x. We used the gnlr function in the R software programme, which fits nonlinear 
regression equations to data for various common one and two parameter error distributions, 
including the binomial distribution, by minimizing the -log-likelihood via the Newton-
Raphson iterative method, to fit both models in this study (see details in 49). The hypothesis 
that the threshold model fits the relationship between community mf prevalence and LF 
disease prevalence better than the nonthreshold model is assessed by comparing the –log 
likelihood values of each model. The null hypothesis is H0: τ = 0 and the alternate hypothesis 
is H1: τ > 0. The test statistic is the likelihood ratio statistic: LR = -2(ln L(H0) – ln L(H1)), 
where L(H0) is the –log likelihood value of the model without a threshold (model 1) and 
L(H1) is the –log likelihood value of the model with the threshold level (model 2). The null 
hypothesis is rejected if the statistic, LR, is greater than 3.84 (critical value, α = 0.05). Note 
that although data from two of the major endemic regions are used in this study, we were able 
only to fit the models to all the available data and hence effectively are able to estimate the 
global threshold value for the association between mf prevalence and LF chronic disease for 
the overall data. Our efforts at fitting the threshold models used in this study to the data when 
stratified by endemic regions failed to converge, most certainly due to the paucity of such 
data and especially the restricted ranges of x-values (mf prevalences) observed for the 
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available studies at the regional level. As in the case of estimating transmission endpoints 5, 
this result clearly highlights the key need for generating standardized regional data over the 
full range observed in the field (but especially over the lower mf prevalence range) if these 
more pertinent regional figures are to be reliably estimated.  
 
Predicting the impact of MDA interventions. Investigation of the impact of using the 
estimated mf prevalence threshold for filarial disease as an intervention endpoint in MDA 
programmes was carried out by simulation using EPIFIL, a deterministic model for LF 
transmission 5,16,17. Simulations predicting annual changes in overall community mf 
prevalence following a 5-year intervention programme with either of the two major MDA 
regimens (viz. annual single dose diethylcarbamazine in combination with albendazole 
(DEC/ALB) or ivermectin in combination with albendazole (IVM/ALB)) with the 
assumption of a pre-control mf prevalence of 10% were compared for treatment coverages of 
65%, 80% and 95%. Drug efficacy values used in the simulations were: DEC/ALB – 55% 
worm kill, 95% mf cured and 6 months mf suppression; IVM/ALB – 35% worm kill, 99% mf 
cured and 9 months mf suppression 17.  
 
Marginal cost-effectiveness analysis. This was performed by combining model predictions 
of the dynamic impact of an annual IVM/ALB MDA programme given at 80% coverage in 
curing individuals of mf with the costs of carrying out this MDA programme. The major 
objective of this analysis was to determine and evaluate the marginal costs of curing 
additional individuals to achieve parasite elimination and eradication of transmission 
compared to achieving disease control in a major endemic country. We illustrate the results 
by basing the analysis on the real life situation in Tanzania, where the endemic pre-control 
LF infection level has been estimated to be around 11.95 % mf prevalence 50. The analysis 
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assumed that the entire current population of Tanzania above 5 years is at risk and so eligible 
for treatment (corresponding to 28.79 million as estimated in 2002 51). Model predictions of 
the impact of the annual IVM/ALB MDA given at 80% coverage for a baseline mf 
prevalence of 11.95% were used in the calculations of the mean number of individuals cured 
during the MDA programme, with the assumption that LF is eliminated when mean mf 
prevalence is reduced to <0.5% 5. Two types of programme costs were estimated and 
compared. First, the total programme cost accounting for all resources (including drug and 
programme delivery costs) used in carrying out an annual MDA, which was conservatively 
assumed to be around $0.70 for treating one individual 18,21. Second, government costs, 
defined as the financial costs of all inputs paid for directly by the Ministry of Health 
excluding any donations to the programme such as donated drugs. We estimated this cost to 
be around $0.53 per treated individual using the estimates given in Ramzy and colleagues 21. 
The former approach is useful in assessing the allocation of programme resources and their 
opportunity costs, i.e. determining whether these resources could be used more productively 
elsewhere, whereas the latter cost estimates are helpful to national planners in assessing 
programme affordability. Numbers of individuals cured and all costs were discounted at 
6.00%. 
 
Modelling the cost of sequential-decision approaches based on chronic disease control. 
We evaluated the strategic value of implementing a sequential decision approach to LF 
eradication in which chronic disease control is first achieved followed by additional MDAs to 
achieve parasite eradication when information regarding the feasibility of eradication 
improves over time, by undertaking a scenario-based analysis of the comparative costs of a 
programme aimed from the beginning solely at eradication versus a two-staged strategy based 
initially on disease control as follows. The analysis was based on EPIFIL predictions of the 
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number of annual MDAs required to meet the endpoints of these scenarios given the baseline 
endemic mf infection prevalence level of 11.95% estimated for Tanzania and a drug coverage 
level of 80%.  
First, we considered the cost of the base strategy in which we are certain that parasite 
eradication can be achieved in 10 years (Table 2). The expected present value cost (EPVC) of 
this strategy is given by: 
∑
=
+
+=
10
2
11 )1(t t
t
r
CCEPVC      (4) 
 
where C1 is the estimated cost of MDA in year 1 (calculated at a per capita cost of $0.70 per 
person (see above)), Ct denotes the cost of MDA for each of the years 2 to 10, and r 
represents the discount rate (6% as above).  
 In scenario two, we assume that information regarding the feasibility of eradication 
becomes clear only some time in the future, say in year 5 following repeated annual MDAs 
(i.e. at the disease control threshold) when we will either know with a high probability, p = 
0.90, that eradication is possible by year 10 in which case we will continue with 5 more 
annual MDAs to achieve eradication or we will know with a probability 1-p = 0.10 that 
eradication is not achievable with the current knowledge and/or technology. At this point, we 
may abandon the goal of eradication and switch to long-term control, i.e implement treatment 
every 10 years (calculations shown here for at least up to 35 years), thus allowing flexibility 
to wait for further information to resolve uncertainty to aide making the choice that 
maximizes the value and minimizes loss from the MDA programme (as a result of reinfection 
to baseline levels if eradication is not achieved). 
 In scenario three, we model the situation similar to scenario 2, but instead of 
considering that eradication is never possible, we consider that uncertainty in present 
knowledge and technology is likely to be resolved by years 10 and 15 post initial MDA, 
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when the probability of eradication will occur at p = 0.90, and eradication then given model 
predictions is expected to be possible with an extra three years of annual MDA following 
disease control with 5 annual MDAs initially. 
 The EPVC of scenario two is hence given by: 
∑∑∑
===
+
−+
+
+
+
+=
35,25,15
10
6
5
2
12 )1(
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t
t
t
t
t
t
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r
CCEPVC  (5) 
 
where C1, Ct and r are described as above and p denotes the probability that eradication is 
possible (=0.90). 
 For scenario three, in which disease control is followed by the switch to eradication 
when information regarding the feasibility of eradication becomes better known either in year 
10 or year 15, the EPVC for the year 10 case is given by: 
∑∑∑
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and for the year 15 case by: 
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with variables as described before. 
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FIGURE LEGENDS 
 
Figure 1. The association between prevalence of Wuchereria bancrofti microfilarial infection 
and prevalence of combined lymphoedema and hydrocele disease in filarial endemic 
communities from Sub-Saharan Africa (○) and India (●). Field study references (n=76) are 
given in Supplementary Table 1 online. All mf prevalence values have been standardized to 
reflect sampling of 1ml blood volumes (see text). The curve shows the best-fit logistic 
regression-based dose-response model incorporating a threshold parameter (equation 2) for 
the overall data with estimated values for a and τ of 1.07% (95% confidence limits (CLs): 
0.54 to 1.60%) and 3.55% (95% CLs: 2.35 to 4.75%), respectively. Details of goodness of fit 
of the model given in Supplemetary Figure 1 online. 
 
Figure 2. (a) Simulation results showing annual changes in overall community mf prevalence 
(scaled to 1ml blood sampling volume) predicted by a deterministic model for filariasis 
transmission following a 5-year annual intervention programme with either the DEC/ALB 
(solid lines) or IVM/ALB (dashed lines) drug regimen. Initial community mf prevalence was 
set at 10%, and for each regimen predictions are shown for treatment coverages of 65%, 80% 
and 95% (portrayed by curves going from top to bottom respectively for each regimen). 
Upper horizontal dashed line shows the disease control mf threshold of 3.55%, while the 
lower line depicts the parasite elimination threshold of 0.5% mf prevalence. All figures are 
given at the scale of 1ml blood sampling volume. Drug efficacy values are as given the text.  
(b) Numerical projections (dashed curves) of changes in LF infection prevalence (Mf % at 
1ml blood sampling scale) following different levels of reduction from initial equilibrium 
infection prevalence induced by annual MDA, as predicted by the EPIFIL model. Note that 
the greater the reduction of initial prevalence to below the mean disease threshold of 3.55 mf 
prevalence (solid horizontal line), the longer it will take to rebound to this threshold. For 
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example, a reduction to a mf prevalence of 2.175% following annual MDA (second dashed 
curve from the bottom) will take up to 12 years to rebound to the disease incidence threshold.  
 
Figure 3. Marginal effectiveness (numbers of individuals cured of mf) and costs of annual 
mass IVM/ALB chemotherapy against LF in Tanzania and the determination of the optimal 
level of parasite control. Simulations of costs and effectiveness are based on the cost and 
demographic details given in Table 2 and the impact of annual IVM/ALB mass treatment (at 
80% coverage) on the prevalence of LF infection predicted by EPIFIL assuming the baseline 
Mf prevalence of 11.95% (at 1ml blood sampling volume) in Tanzania. Annual costs and 
effectiveness are both expressed as a fraction of their total discounted figures following 10 
years of intervention (Table 2). The results show that the maximum number of individuals 
cured of mf per unit cost occurs at 85% parasite control following 3 years of annual MDA 
closer to achieving the long-term disease control target of 2.35% (see text) than the target of 
100% parasite control or elimination. 
 
Figure 4. The relationship between Expected Present Value Costs (EPVCs) of implementing 
Strategies 3a (S3a) and 3b (S3b) (see text) and the probability of LF eradication for the 
Republic of Tanzania. The lines show that as the uncertainty regarding the feasibility of 
eradication increases (probability of eradication becomes lower) the expected costs of these 
flexible strategies decline dramatically. 
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Table 1. Parameters and negative log-likelihoods for the logistic dose-response models 
with and without a threshold fitted (see text) to the mf – LF chronic disease prevalence 
data (n = 76) 
 
 
Model 
 
α 
Value of: 
β 
 
τ 
- log likelihood LR+ 
1 1.02 
(0.096) 
0.27 
(0.005) 
- 2720.635  
2 1.07 
(0.530) 
0.34 
(0.008) 
3.55 
(1.196) 
2230.311 15.817* 
 
~ figures in brackets denote the standard errors estimated for each parameter 
+ Likelihood ratio statistic (see text) 
* p < 0.0001 
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 Table 2. Predicted average and marginal costs of an annual IVM/ALB MDA programme 
to control disease or eliminate LF transmission in the Republic of Tanzania 
 
Programme Cost 
(US$)3 
No. of 
individuals 
cured of mf 
Ratio of Total 
cost to no. of 
individuals 
cured of mf  
(US$ per 
individual)3 
Ratio of Govt 
cost to no. of 
individuals 
cured of mf  
(US$ per 
individual)4 
 
1. Disease control (5 
years of annual 
MDA)1 89,949,942 
 
2,467,830 
 
36.45 
 
27.60 
 
2. Transmission       
Elimination (10 years 
of annual MDA)2 157,165,771 
 
2,790,395 
 
56.32 
 
42.65 
 
3. Increment (of 
Programme 2 over 
Programme 1)5 67,215,829 
 
322,565 
 
208.38 
 
157.77 
 
 
1 Represents a programme targeted at disease control assumed to occur when the mf 
prevalence is reduced long-term (for at least 10 years) to below 3.99% (Fig. 2a). For a 
baseline prevalence of 11.95% mf prevalence, it is predicted to take up to 5years of MDA 
with IVM/ALB to reduce infection prevalence to 2.3% to achieve this objective at 80 % 
coverage. 
2 Represents a programme to eliminate parasite transmission assumed to occur when the 
mf prevalence is reduced to just below 0.5%. For a baseline prevalence of 11.95 % mf 
prevalence, it is predicted to take up to 10 years of MDA with IVM/ALB to achieve this 
target at 80 % coverage. 
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3 The full economic cost of the programme, including the cost of donated drugs and 
programme delivery costs borne by the Government estimated at $0.70 for treating each 
individual. 
4 Excludes the cost of donated drugs. Estimate of drug costs to total programme cost 
obtained from ref (24.2%) is used in calculating only the additional Government cost 
involved in delivering the MDA programme. Effectively, this decreases the per capita 
cost of treating an individual from $0.70 per individual for the total cost estimation to 
$0.53 per individual for the Government costs only estimation. 
5 Addition individuals cured of mf and the total and average marginal costs of curing 
these individuals to achieve parasite transmission elimination from a programme targeted 
at disease control. 
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Table 3. Present value costs of LF eradication strategies for the Republic of Tanzania 
with and without sequential-decision making flexibility based on exercising chronic 
disease control options 
 
Strategy1 Design EPVC2 Option 
Value3 
 
S1 
 
Inflexible: 10 year annual MDA  
 
157,165,771 
 
 
 
S2 
 
Flexible: Switch to long-term disease 
control after 5 years of annual MDA when 
it becomes evident eradication is not 
possible 
 
 
 
 
152,110,572 
 
 
 
 
5,055,199 
 
S3a 
 
Flexible: Switch to eradication with 3 
extra annual MDAs from year 10 
following disease control with 5 initial 
annual MDAs 
 
 
 
153,822,682 
 
 
 
3,343,089 
 
S3b 
 
Flexible: Switch to eradication with 3 
extra annual MDAs from year 15 
following disease control with 5 initial 
annual MDAs 
 
 
 
152,968,795 
 
 
 
4,196,976 
 
 
1 Denotes the three different scenarios described in detail in the text. 
2 Expected present value cost of each strategy in US$. 
3 The difference between the EPVCs of flexible stategies 2 to 3 over strategy 1. 
Represents the value (costs saved here) of retaining the option to switch between 
eradication and disease control depending on the state of eradication feasibility. 
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